Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04379414 · ClinicalTrials.gov registry record · NA

YES Study - Newly Diagnosed/Metastatic Intervention

A NA study of Breast Cancer and Symptom, Behavioral, sponsored by Dana-Farber Cancer Institute.

Active
Registry status
NA
Development phase
400
Enrollment target
1
Study location

NCT04379414 is a NA study of Breast Cancer and Symptom, Behavioral that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 400 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04379414, a NA study of Breast Cancer and Symptom, Behavioral, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
400 participants
Enrollment target
1
Study location

Study Summary

This research study is being done to monitor common symptoms and behavior, and to provide supportive care information and peer support, as well as research opportunities for young women ages of 18-39 years old who have been diagnosed with stage 0-IV stage breast cancer using a web-based portal (YES), built for smartphones, tablets, and computers.

Interventions

  • BEHAVIORAL YES portal

Study Locations (1)

Massachusetts

  • Dana Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2020-09-16
Est. Completion 2028-03-01
Phase NA

Sponsor

Dana-Farber Cancer Institute

781 total trials

What the Registry Record Tells You About NCT04379414

The ClinicalTrials.gov registry entry for NCT04379414 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (86% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which YES portal is the first listed.

NCT04379414 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04379414 about?

NCT04379414 is a clinical study titled "YES Study - Newly Diagnosed/Metastatic Intervention". This research study is being done to monitor common symptoms and behavior, and to provide supportive care information and peer support, as well as research opportunities for young women ages of 18-39 years old who have been diagnosed with stage 0-IV stage breast cancer using a web-based portal (YES)...

What is the current status of trial NCT04379414?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 400 participants. The study started on 2020-09-16. Estimated completion is 2028-03-01.

What conditions does trial NCT04379414 study?

This clinical trial studies the following conditions: Breast Cancer, Symptom, Behavioral.

What interventions are being tested in trial NCT04379414?

The interventions under investigation include: YES portal (BEHAVIORAL).

Who is sponsoring clinical trial NCT04379414?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04379414 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.